Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Matthew B. Rettig, M.D.
Matthew B. Rettig, M.D.

Specialty:

Internal Medicine
Medical Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Associate Professor in Residence, Department of Medicine, Hematology/Oncology
Member, JCCC Cancer and Stem Cell Biology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Internal Medicine, UCLA School of Medicine, 1993 - 1996
Residency:
Internal Medicine, University of Washington School of Medicine, 1991 - 1993
Internship:
Internal Medicine, LAC+USC Medical Center, 1990 - 1991
Medical Degree:
M.D., Duke University School of Medicine, 1990

Certification(s):

Medical Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 1998
Internal Medicine, American Board of Internal Medicine, 1996

Contact Information:

Phone:
(310) 206-2436
Email:

Scientific Interest(s):

Dr. Matthew Rettig's research focuses on the molecular and cellular biology of multiple myeloma, the role of human herpesvirus-8 in pathogenesis of myeloma and latent human herpesvirus-8 proteins that upregulate the transcription of cellular interleukin-6.

Selected Cancer-Related Publications:

An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther. 2007; 6(1): 61-9.

An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 2005; 25(17): 7546-56.

Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004; 64(2): 335-40.

An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003; 9(12): 4537-45.

An J, Sun Y, Sun R, Rettig MB. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003; 22(22): 3371-85.